Global Liquid Biopsy Market Growth, Share, Size, Trends and Forecast (2023 - 2029)

This report extensively covers different segments of Global Liquid Biopsy Market and provides an in depth analysis (including revenue analysis for both historic and forecast periods) for all the market segments. In this report, the analysis for every market segment is substantiated with relevant data points and, insights that are generated from analysis of these data points (data trends and patterns).

Global Liquid Biopsy Market Analysis

In this report, the Global Liquid Biopsy Market has been segmented by Application, Type, Technology and Geography. Liquid biopsy is a noninvasive diagnostic test which can identify various types of cancers. The rising prevalence of cancer among the people is driving the growth of global liquid biopsy market.

Global Liquid Biopsy Market, Segmentation by Geography

In this report, the Global Liquid Biopsy Market has been segmented by Geography into five regions; North America, Europe, Asia Pacific, Middle East and Africa and Latin America.

Find below the list of Countries covered in each of the aforementioned geographical regions:

North America - United States, Canada and Mexico

Latin America - Brazil, Argentina and Rest of Latin America

Europe - Germany, United Kingdom, France, Italy, Spain and Rest of Europe

Asia Pacific - Japan, China, India, Australia & New Zealand, South Korea, ASEAN (Association of South East Asian Nations) and Rest of Asia Pacific

Middle East & Africa - GCC Countries, Egypt, Israel, South Africa, Rest of Middle East & Africa

This report provides market size in USD Million and Year on Year (YOY) percentage growth analysis for the Liquid Biopsy Market in all the Regions and Countries (specified above) for historic (2019 - 2022) and forecast (2023 - 2029) Periods with 2022 considered as the base year.

This report also provides an analysis of why the market size of Liquid Biopsy in various regions and countries is increasing or decreasing with time along with the reasons for changes in the YOY growth with time.

This report provides an in depth analysis of various factors that impact the dynamics of Global Liquid Biopsy Market. These factors include; Market Drivers, Restraints and Opportunities Analysis, Market Opportunity Mapping, PEST (Political, Economic, Social and Technological) Analysis and Porter's Five Forces Analysis.

Drivers, Restraints and Opportunity Analysis

Market Opportunity Map

This report provides market opportunity map for Liquid Biopsy Market. The opportunity map (by market segments; Application, Type and Technology) is calculated based on current year market estimates, CAGR and collective revenue over the forecast period. Since, CAGR has been estimated considering all the factors impacting the market; starting from the company's presence, buyer behaviour, to government interference or support. The opportunity map inherently considers all the aforementioned factors impacting the market. The bubble size reflects the estimated opportunity for a particular segment or region, therefore, bigger the bubble size, larger the opportunity.

PEST (Political, Economic, Social and Technological) Analysis

This report provides PEST analysis of Liquid Biopsy Market. Various factors such as government interference in the market such as regulations (which include but are not limited to pricing and intellectual property policies) that might impact the market are analysed.

This report also provides an analysis of Economic factors affecting the market such as; purchasing power, which directly influences the market growth.

This report also provides an analysis of social factors such as social norms or cultural beliefs inhibiting or promoting the growth of the market

As part of PEST analysis, this report also provides analysis of the impact of Technological factors on growth or decline of a market.

Porter's Five Force Analysis

This report provides Porter's Five Forces analysis of Global Liquid Biopsy Market, which include; Bargaining Power of Suppliers, Bargaining Power of Buyers, Threat of New Entrants, Threat of Substitutes and Competitive Rivalry.

Bargaining Power of Suppliers:

Various factors such as; Supplier Switching Costs Relative to Firm Switching Costs, Supplier Competition and Possibility of Forward Integration, Presence of Substitute Inputs, Strength of Distribution Channels, and Supplier Concentration to Firm Concentration Ratio would be analysed to estimate bargaining power of suppliers in the Global Liquid Biopsy Market. Bargaining power of suppliers will be reported on a scale of 0-10 with 0 being the lowest value and 10 being the highest value. Clinical omics has released a new list of 10 privately held diagnostics developers with a primary focus on liquid biopsy assays, including grail. As declared by the companies themselves in press releases or other public sources, the companies are ranked according to the total amount of capital they have raised. Researchers are looking into the potential of liquid biopsies as a means to better detect cancer at an early stage, aid in the selection of an appropriate treatment plan, monitor the effectiveness of that plan, and assess whether or not the disease is progressing. Many of the current liquid biopsy tests being developed are meant to detect very precise alterations, or mutations, in dna that are linked to certain types of cancer. During the epidemic, protective health is aiding cancer treatment. The myriad genetics liquid biopsy is a simple blood test that helps cancer patients obtain the answers they need. The company is at the forefront of molecular diagnostics, and its mission is to save lives through the development and distribution of tests for all major diseases. Correct medication. Liquid biopsies of stock soon may allow for early cancer diagnosis than ever before. The life of guillermo. Liquid marketing is a beverage company that works to influence popular alcohol labels served in pubs. Located in the hub of london's bustling cocktail bar scene in shoreditch, this dynamic firm is equally focused on marketing and sales, resulting in a more streamlined, quick-witted, and technologically savvy enterprise. Can a liquid biopsy identify cancer before a tumour forms? Entails examining a patient's blood for cancerous prostate cell (pca) tumour cells or other genomic indicators such cell-free tumour dna and rna. Clinical trials are currently being conducted with patients who have had a recurrence of prostate cancer after therapy or who have advanced or metastatic disease detected by a blood test called a liquid biopsy. The results of genomic assays like illumina's trusight tm oncology 500 (tso 500) could be used to significantly improve cancer care and treatment monitoring. However, more validation is needed to adequately demonstrate the clinical value of liquid biopsy at this point in its development. Patients on maintenance therapy for breast cancer with ctdna drugs like tamoxifen, for example, typically have to wait five years to find out if their cancer has fmi naterra advanced, but a liquid biopsy can provide that information in a matter of months. The signatera test is the first ctdna test designed specifically for each patient's tumour based on its specific mutations. Multiple clinical studies have demonstrated that signatera fmi naterra is effective at detecting molecular residual disease at considerably earlier stages in patients with non-small cell lung, bladder, breast, and colorectal malignancies.

Bargaining Power of Buyers:

Various factors such as; Buyer Concentration to Firm Concentration Ratio, Buyer Switching Costs, Availability of Existing Substitute Products, Buyer Price Sensitivity, and Degree of Dependency upon Existing Channels of Distribution would be analysed to estimate bargaining power of buyers in the Global Liquid Biopsy Market. Bargaining power of buyers will be reported on a scale of 0-10 with 0 being the lowest value and 10 being the highest value.

Threat of Substitutes:

Various factors such as; Availability of Substitutes, Number of Available Substitutes, Price of Substitute Products, Buyer Switching Costs, and Buyer Propensity to Substitute would be analysed to estimate threat of substitutes in the Global Liquid Biopsy Market. Threat of substitutes will be reported on a scale of 0-10 with 0 being the lowest value and 10 being the highest value.

Threat of New Entrants:

Various factors such as; Barriers to Entry, Economies of Scale, Product Differentiation, Customer Loyalty, Network Effect, and Access to Distribution Channels would be analysed to estimate threat of new entrants in the Global Liquid Biopsy Market. Threat of new entrants will be reported on a scale of 0-10 with 0 being the lowest value and 10 being the highest value.

Competitive Rivalry:

Various factors such as; Firm concentration Ratio, Level of Advertising Expense, Sustainable Competitive Advantage through Innovation, Competitive Strategy and Degree of Transparency would be analysed to estimate competitive rivalry in the Global Liquid Biopsy Market. Competitive rivalry will be reported on a scale of 0-10 with 0 being the lowest value and 10 being the highest value.

Key players in Global Liquid Biopsy Market include, Vermillion, Inc., Genomic Health, Inc., Foundation Medicine, Inc., Biocept, Inc., Myriad Genetics, Inc., OncoCyte Corporation, Veracyte, Inc, Inc., Guardant Health, Inc., NeoGenomics Laboratories, Inc., Personal Genome Diagnostics, Inc., QIAGEN, RainDance Technologies, Inc., Adaptive Biotechnologies., Trovagene Inc. and Cynvenio Biosystems.

In this report, the profile of each market player provides following information:

• Company Overview and Product Portfolio
• Key Developments
• Financial Overview
• Strategies
• Company SWOT Analysis

This report also provides Heat map analysis of Products/Services Offered by different companies operating in this market.